Your browser doesn't support javascript.
loading
Clinical utility of pharmacogenetics in a psychiatric and primary care population.
Bohlen, Krista N; Kittelsrud, Julie M; Nelson, Morgan E; Weisser, Lisa K; Matthiesen, Neil J; Fieldsend, Julie A; Buschette, Nicholas B; Cooper, Leslie L; Davies, Gareth E; Ehli, Erik A.
Afiliación
  • Bohlen KN; Avera Institute for Human Genetics, 3720 West 69th Street, Sioux Falls, SD, 57108, USA. Krista.Bohlen@avera.org.
  • Kittelsrud JM; University of South Dakota Sanford School of Medicine, Psychiatry, 1400 West 22nd Street, Sioux Falls, SD, 57105, USA. Krista.Bohlen@avera.org.
  • Nelson ME; Avera Institute for Human Genetics, 3720 West 69th Street, Sioux Falls, SD, 57108, USA.
  • Weisser LK; University of South Dakota Sanford School of Medicine, Psychiatry, 1400 West 22nd Street, Sioux Falls, SD, 57105, USA.
  • Matthiesen NJ; RTI International, Research Triangle Park, NC, USA.
  • Fieldsend JA; Avera Institute for Human Genetics, 3720 West 69th Street, Sioux Falls, SD, 57108, USA.
  • Buschette NB; Avera Institute for Human Genetics, 3720 West 69th Street, Sioux Falls, SD, 57108, USA.
  • Cooper LL; Avera Institute for Human Genetics, 3720 West 69th Street, Sioux Falls, SD, 57108, USA.
  • Davies GE; Avera Institute for Human Genetics, 3720 West 69th Street, Sioux Falls, SD, 57108, USA.
  • Ehli EA; Avera Institute for Human Genetics, 3720 West 69th Street, Sioux Falls, SD, 57108, USA.
Pharmacogenomics J ; 23(1): 21-27, 2023 01.
Article en En | MEDLINE | ID: mdl-36302979
This study evaluated the timing, use, and clinical outcomes of the GeneFolio® Pharmacogenomic Panel in a healthcare setting with patients managed by primary care providers or by psychiatrists. Participants were randomized to receive a pharmacogenetics report at four weeks or 12 weeks. After DNA collection and genetic analysis, pharmacists produced a recommendation report which was given to providers at the randomization week. The four-week group decreased depression severity (PHQ-9 and BDI) faster than the 12-week group (p = 0.0196), and psychiatrists' patients decreased their depression severity faster than primary care patients (PHQ-9 p = 0.0005, BDI p = 0.0218). Mean mental quality of life increased over time (p < 0.0001), but it increased slower for patients taking drugs in the Significant drug-drug-gene interaction category (p = 0.0012). Mental quality of life, depression severity, and clinical outcomes were improved by GeneFolio® pharmacogenomic testing regardless of provider type, with earlier testing improving outcomes sooner.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacogenética / Calidad de Vida Tipo de estudio: Clinical_trials / Guideline Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacogenética / Calidad de Vida Tipo de estudio: Clinical_trials / Guideline Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Pharmacogenomics J Asunto de la revista: BIOLOGIA MOLECULAR / FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos